Daily Roundup:
Cutting back to a lower dose of tirzepatide kept food cravings down in a trial presented at ObesityWeek (Endocrinology Advisor)
Dairy makers say people on GLP-1s are part of why protein demand keeps climbing (FoodNavigator)
Health Canada has signed off on Foundayo, a daily GLP-1 pill from Eli Lilly (Global News (The Canadian Press))
A Penn trial tested semaglutide in adults with obesity, including some with binge eating (PhillyVoice)
Cutting back to a lower dose of tirzepatide kept food cravings down in a trial presented at ObesityWeek
Key Details:
In the SURMOUNT-MAINTAIN trial, adults took the drug for 60 weeks at the highest dose they could handle, then were randomly assigned to stay on that dose, step down to 5 milligrams, or switch to a placebo for another 52 weeks.
Both groups still on the drug kept their lower scores for food cravings and hedonic hunger, which was measured with a scale called the Power of Food Scale.
Twelve weeks after switching to placebo, hedonic hunger and cravings were back to where they started, while weight came back more slowly.
The authors wrote that hedonic hunger and food cravings "may serve as early indicators of treatment withdrawal effects in adults with obesity."
Source: Endocrinology Advisor
Dairy makers say people on GLP-1s are part of why protein demand keeps climbing
Key Details:
Danone, Arla, Yili and Saputo have all pointed to weight-loss drugs as important for protein demand.
Tom Booijink, a dairy specialist at Rabobank, said whey is "at the forefront" of that demand.
He called the drugs a "very powerful catalyst" in an already tight market, but not the "sole driver."
A Danone spokesperson said the drugs are a key part of the company's push into high-protein products, especially because users want to keep their muscle mass.
Source: FoodNavigator
Health Canada has signed off on Foundayo, a daily GLP-1 pill from Eli Lilly
Key Details:
The agency authorized it on November 13 for adults with obesity, and for adults who are overweight with at least one related health problem, like high blood pressure or sleep apnea.
The pill is also approved to help treat Type 2 diabetes, and its active ingredient is orforglipron.
Lilly spokesperson Ethan Pigott said the company expects the pills to be in pharmacies in January.
Novo Nordisk's Wegovy pill is still waiting for approval in Canada.
Source: Global News (The Canadian Press)
A Penn trial tested semaglutide in adults with obesity, including some with binge eating
Key Details:
The 160 adults got the drug or a placebo for 60 weeks, plus counseling on eating and exercise.
The semaglutide group lost about four times as much weight as the placebo group.
Among people who had binge eating before the study, more on the drug went into remission than on placebo.
Senior author Jena Tronieri said the findings suggest semaglutide "not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients."
Source: PhillyVoice
Learn More
Join the free GLP-1 community Cozy Butter: cozybutter.com
Listen to GLP-1 Radio, GLP-1 shows all day: glp1radio.com
Every GLP-1 Studio Daily episode: GLP-1 Studio Daily
About Amanda Bonello: amandabonello.com
This is a reader-supported publication, thank you so much for your support.
💖












